PDCD1 and neoplasm: The results showed that mice bearing B16-F10 tumors treated with combined regimen had longer survival than other groups ((Fig. 1E-H), and tumor samples of mice treated with PD-1 antibody or combined therapy had significantly higher levels of CD3, CD8, and granzyme B than IgG group (Fig. 2F-H).